The α-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes

Several epidemiological studies have shown that postprandial hyperglycemia is associated with an increased risk of cardiovascular disease (CVD). The present study was conducted in order to compare the effects of acarbose and glimepiride treatment on serum lipoprotein profiles in patients with type 2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinica chimica acta 2008-04, Vol.390 (1), p.110-114
Hauptverfasser:	Hasegawa, Goji, Kajiyama, Shizuo, Tanaka, Toru, Imai, Saeko, Kozai, Hana, Fujinami, Aya, Ohta, Mitsuhiro, Obayashi, Hiroshi, Park, Hyohun, Nakano, Koji, Tanaka, Muhei, Shiraishi, Emi, Fukui, Michiaki, Yoshikawa, Toshikazu, Nakamura, Naoto
Format:	Artikel
Sprache:	eng
Schlagworte:	Acarbose - pharmacology Acarbose - therapeutic use Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetic dyslipidemia Electronegative charge modified LDL Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Glycoside Hydrolase Inhibitors Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Lipoprotein particle size Lipoproteins, LDL - metabolism Oxidized LDL Type 2 diabetes α-glucosidase inhibitor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!